PPRXL2A· Business · 7 sources · 1dStoryADARx Raises $446 Million in Upsized IPOADARx Pharmaceuticals raised $446 million in an upsized IPO at $17 a share, the top of its range, and began Nasdaq trading under ADRX with an AbbVie private placement.Business· 1d
PPRXL2A· Finance · 12 sources · 5dStoryADARx Plans $350 Million IPO, AbbVie StakeADARx Pharmaceuticals plans a $350 million IPO by issuing 21.9 million shares at $15-$17 each, with AbbVie investing up to $100 million for about 4.9% of the company, valuing it around $1.8 billion and listing on Nasdaq as ADRX. The biotech focuses on siRNA therapies with three clinical-stage programs and two advanced preclinical programs, led by onvuzosiran in Phase 3 for hereditary angioedema, with pricing anticipated the week of September 21, 2026.Finance· 5d
